Immunoassays News and Research

RSS

Lateral flow assays detect a compound of interest in a compact, paper-based system. Tests such as pregnancy tests are based on lateral flow assays, with many more available for various compounds or even pathogens.

Intranasal inoculation study sheds light on nasal and systemic immune responses to SARS-CoV-2

Study reveals the events accompanying the COVID-19 infection cascade in the nasal mucosa and free circulation

1 Aug 2023

Gyros Protein Technologies introduces PurePep EasyClean Auto Kit for automated parallel peptide purification

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of its PurePep® EasyClean (PEC) Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.

From Gyros Protein Technologies AB 31 Jul 2023

Shaping the human metabolome: the impact of a ketogenic diet

Researchers explored how the human metabolic fingerprint changes with a ketogenic diet (KD).

6 Jun 2023

CSEM collaborates with innovative Swiss start-up MOMM diagnostics to introduce revolutionary preeclampsia test

CSEM’s Tools for Life Sciences team is partnering with MOMM Diagnostics to develop a cutting-edge point-of-care solution for preeclampsia diagnostics. This ground-breaking multiplexed sensing device simultaneously detects two crucial biomarkers associated with this prevalent disease.

From CSEM 31 May 2023

Analyzing impact of phospholipase D on the host immune response to A. fumigatus infection

Announcing a new article publication for Zoonoses journal. Aspergillus fumigatus infection in the lungs is accompanied by the recruitment of innate immune cells, phagocytosis, and the release of inflammatory factors.

11 May 2023

COVID-19 risk: natural immunity vs. vaccine induced immunity

Researchers evaluated the immune protection conferred by previous SARS-CoV-2 infection and/or COVID-19 vaccines.

4 May 2023

Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

From Gyros Protein Technologies AB 4 May 2023

Gyros Protein Technologies introduces new PurePep EasyClean services to accelerate development and manufacturing of peptide-based drugs

Gyros Protein Technologies AB today announced the launch of three service offerings to support development and manufacturing of peptide-based drugs.

From Gyros Protein Technologies AB 22 Mar 2023

Playing tackle football at an early age increases risk for brain decline later

The degenerative brain disease known as CTE, or chronic traumatic encephalopathy, has become a specter haunting football.

20 Mar 2023

Study shows SARS-CoV-2 causes DNA damage and elicits an altered DNA damage response

Researchers assessed the association between SARS-CoV-2 infection and DNA damage and cellular senescence.

14 Mar 2023

The effects of Omicron emergence on seroprevalence and hybrid immunity in the Finnish adult population

Researchers evaluated SARS-CoV-2 seroprevalence and population-level humoral immunity among Finnish individuals between April 2020 and December 2022.

28 Feb 2023

The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals

Researchers determined the prevalence of antibodies against the SARS-CoV-2 spike glycoprotein following three or more doses of COVID-19 vaccines among immunocompromised individuals.

17 Feb 2023

Cellular and humoral responses and the safety of recombinant and inactivated SARS-CoV-2 vaccines in chronic kidney disease patients

Researchers investigated the B cell and humoral immune responses elicited against inactivated and recombinant SARS-CoV-2 vaccines and their safety profiles in patients with CKD.

8 Feb 2023

Researchers develop a new multi-omics microsampling method for complete health profiling

Researchers developed a multi-omics-based microsampling workflow for profiling proteins, metabolites, lipids, and specific cytokines and hormones, i.e., multiple analytes, in a single blood sample of 10 μl (microsample).

26 Jan 2023

Review on lateral flow test use spearheaded by SARS-CoV-2 pandemic

Researchers assessed the changing landscape of lateral flow tests (LFTs), and the development of next-generation LFTs based on lessons learnt from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

23 Jan 2023

InDevR raises $9 million in series B financing and partners with bioMérieux

New partnerships will drive the commercial expansion of InDevR’s game-changing solutions for vaccines and biotherapeutics.

20 Jan 2023

Study investigates the spectrum of antibody immunity across several SARS-CoV-2 variants

Researchers evaluated antibody responses to the spike proteins of the SARS-CoV-2 Wuhan-Hu-1 strain and VOCs such as the Alpha, Beta, Gamma, Delta, and Omicron.

16 Jan 2023

What is the global state of SARS-CoV-2 seroprevalence in children?

Researchers conducted a systematic review to assess global pediatric SARS-CoV-2 seroprevalence.

3 Jan 2023

Study demonstrates robust antibody response elicited by trivalent protein subunit vaccine against SARS-CoV-2

Researchers demonstrated that a trivalent vaccine against SARS-CoV-2 improved the breadth of humoral immune responses in mice.

19 Dec 2022

Study finds anti-S binding antibody levels are a valid correlate of protection against Omicron BA.1/BA.2 infections

Researchers used serological measurements from a longitudinal cohort to evaluate the use of binding antibodies against the SARS-CoV-2 spike protein receptor binding domain as correlates of protection against the immune evasive Omicron subvariants BA.1 and BA.2.

16 Dec 2022